ライフサイエンスコーパス: substance dependence

1 icit disorder), CNTF (psychosis), and OPRM1 (substance dependence).

2 t GSK598809 may remediate reward deficits in substance dependence.

3 redict suicidal behavior among patients with substance dependence.

4 e factors in the development of each type of substance dependence.

5 al ideation and clear intent, and those with substance dependence.

6 e, and 5) lifetime psychiatric disorders and substance dependence.

7 y of alcoholism predicted the development of substance dependence.

8 nosis of schizophrenia, bipolar disorder, or substance dependence.

9 y provide a biomarker for the development of substance dependence.

10 disorders, including Parkinson's disease and substance dependence.

11 what has been found in schizophrenia without substance dependence.

12 in patients with comorbid schizophrenia and substance dependence.

13 sk of relapse for patients with co-occurring substance dependence.

14 severity without an increase in severity of substance dependence.

15 bens, holds promise as a pharmacotherapy for substance dependence.

16 sorder is associated with very high rates of substance dependence.

17 who met DSM-IV-TR criteria for both PTSD and substance dependence.

18 development of individualized treatments for substance dependence.

19 on of cognitive-behavioral therapy (CBT) for substance dependence.

20 findings regarding association of DRD2 with substance dependence.

21 common clinical problem in individuals with substance dependence.

22 nd in relation to improvement in severity of substance dependence (0.43 vs 0.52; incidence rate ratio

23 significant anxiety (57.1%), and history of substance dependence (44.4%).

24 nder balanced) and was associated with adult substance dependence, adult life impairment, and treatme

25 ted for major depression, anxiety disorders, substance dependence (alcohol and drug dependence), and

26 g 382 European Americans (EAs) affected with substance dependence [alcohol dependence (AD) and/or dru

27 A history of MDD prior to lifetime onset of substance dependence also reduced the likelihood of remi

28 d symptoms can be effective in patients with substance dependence, although results have not been con

29 With the exception of past-year substance dependence and abuse/dependence combined, ther

30 The children of fathers with both substance dependence and antisocial personality disorder

31 However, families with paternal substance dependence and antisocial personality disorder

32 Children of fathers with substance dependence and antisocial personality disorder

33 Overlap in the gene locations for substance dependence and BMI suggests that a common gene

34 (58% AA) diagnosed with opioid and/or other substance dependence and control subjects.

35 cebo-controlled trials of patients with both substance dependence and depression, applied the inclusi

36 adjunct to standard outpatient treatment for substance dependence and may provide an important means

37 ining from smoking, overlap with genetics of substance dependence and memory, and nominate gene varia

38 uals could improve effectiveness of treating substance dependence and preventing drug abuse relapse.

39 ses revealed that genes influencing risk for substance dependence and related phenotypes, such as bod

40 Substance dependence and schizophrenia are both associat

41 with diagnoses of a personality disorder or substance dependence and some normal comparison subjects

42 rtant factor in the remission and relapse of substance dependence and substance use.

43 ug-free patients with both schizophrenia and substance dependence, and 15 healthy controls.

44 lifetime psychiatric disorders, and lifetime substance dependence, and 3) explore the stress-bufferin

45 SM-III-R diagnosis of nonalcohol nonnicotine substance dependence, and 8.1% and 5.2% for antisocial p

46 tent mental health problems (eg, depression, substance dependence, and additional suicide attempts) c

47 ers represented separate affective, anxiety, substance dependence, and antisocial factors.

48 views to assess prevalence of mental health, substance dependence, and comorbid psychiatric disorders

49 ention-deficit/hyperactivity disorder, prior substance dependence, and posttraumatic stress disorder

50 ing the indexing terms naloxone, naltrexone, substance dependence, and substance withdrawal syndrome.

51 nment (SAGE); the Yale-Penn genetic study of substance dependence; and the National Health and Resili

52 etween the child's psychopathology, paternal substance dependence/antisocial personality disorder sta

53 Paternal substance dependence/antisocial personality disorder sta

54 cally for patients with bipolar disorder and substance dependence, appears to be a promising approach

55 r, becoming apparent that sex differences in substance dependence are also influenced by genetic fact

56 Binge eating and substance dependence are disorders characterized by a lo

57 disorder, obsessive-compulsive disorder, and substance dependence are not likely to share a common ca

58 n which 77 individuals seeking treatment for substance dependence at an outpatient community setting

59 nmental influences increase in importance as substance dependence becomes more specialized in adultho

60 nternalizing psychopathology than those with substance dependence but not antisocial personality diso

61 Substance dependence can be thought of as a pharmacogene

62 iterion count was performed in 3 independent substance dependence cohorts (the Yale-Penn Study, Study

63 r, psychosis, posttraumatic stress disorder, substance dependence, current abuse, intellectual disabi

64 participants had 1 or more mental health or substance dependence diagnoses; 1 in 5 (20.1%) had 2 or

65 lence and comorbidities of mental health and substance dependence disorders assessed via the Mini-Int

66 Antisocial behavior and substance dependence disorders exact a heavy financial a

67 urgently needed to address mental health and substance dependence disorders in this population.

68 Other DSM-III-R substance dependence disorders varied in the stability o

69 background and diagnoses of psychiatric and substance dependence disorders.

70 good to excellent (kappas >/=0.65) for most substance dependence disorders.

71 ) and externalizing (antisocial personality, substance dependence) disorders in statistically predict

72 rapid cycling, medication, alcohol or other substance dependence, duration, and mood state.

73 s (CDS), and a composite index of antisocial substance dependence (DV + CDS).

74 icated in addictive-like eating behavior and substance dependence: elevated activation in reward circ

75 Alcoholism and substance dependence frequently co-occur.

76 Families with paternal substance dependence functioned worse than normal compar

77 Substance dependence has a substantial genetic component

78 al population studies have demonstrated that substance dependence has a substantially heritable compo

79 eceptor genes that have been associated with substance dependence have been determined to be function

80 ls in neural functioning between obesity and substance dependence have been found, to our knowledge,

81 People with substance dependence have health consequences, high heal

82 rder (HR, 1.70; 95% CI, 1.05-2.75; P = .03), substance dependence (HR, 2.96; 95% CI, 1.24-7.08; P = .

83 the occurrence of depression in relation to substance dependence in evaluating suicidal risk among s

84 e for a genetic component in the etiology of substance dependence in Native Americans, including stud

85 tigated the role of genetics in the risk for substance dependence in Native Americans.

86 d risk was not further increased by comorbid substance dependence in probands.

87 ion for chromosome 11 gene cluster SNPs with substance dependence, including extension of liability t

88 entification of neurocognitive predictors of substance dependence is an important step in developing

89 with regard to the use of alcohol and drugs, substance dependence is one of the primary sources of he

90 tal circuits is an area of great interest in substance dependence literature, particularly as the fie

91 etime diagnoses of alcohol dependence, other substance dependence (marijuana, cocaine, other stimulan

92 r depressive disorder (MDD) on the course of substance dependence may differ depending on the tempora

93 uniformly stable against confounding: axis I substance dependence or abuse disorders and axis II pass

94 hat an individual with a lifetime history of substance dependence or habitual smoking at the first in

95 These subjects had diagnoses of substance dependence or personality disorder (PD) or wer

96 orders, major depression, substance abuse or substance dependence, or panic attacks.

97 ther specific psychiatric disorders, notably substance dependence, panic and generalized anxiety diso

98 dhood self-control predicts physical health, substance dependence, personal finances, and criminal of

99 Other candidate genes associated with substance dependence phenotypes in Native Americans incl

100 ied genes with variants associated with four substance dependence phenotypes or five psychiatric diso

101 d might biologically bridge OD and other non-substance dependence psychiatric traits where similar pa

102 ing childhood maltreatment, tobacco smoking, substance dependence, psychiatric medication use, poor p

103 h groups improved significantly over time on substance dependence, psychotic symptoms, homelessness,

104 Subjects underwent a detailed evaluation of substance dependence-related traits.

105 The development of substance dependence requires the initiation of substanc

106 fect genes previously known to contribute to substance dependence risk.

107 Subjects ascertained for genetic studies of substance dependence (SD) and diagnosed with ASPD and co

108 ted to be part of the inherited component of substance dependence (SD) risk.

109 The high rates of substance dependence seen in some tribes is likely a com

110 he timing of depressive episodes relative to substance dependence served as an important factor in th

111 DSM-IV indicates that diagnoses of substance dependence should be further characterized wit

112 on, patients with comorbid schizophrenia and substance dependence showed significant blunting of stri

113 y subjects (control group), 26 subjects with substance dependence (substance-dependent group), and 21

114 Among patients with PTSD and substance dependence, the combined use of COPE plus usua

115 and NCAM1 are functional candidate genes for substance dependence; the TTC12 and ANKK1 loci are not w

116 reconcile the conflicting associations with substance dependence traits, we performed a meta-analysi

117 o patients with bipolar disorder and current substance dependence, treated with mood stabilizers for

118 tigated the effects of MDD on the outcome of substance dependence under 3 circumstances: (1) lifetime

119 The stability of diagnosis for other substance dependence varies from substance to substance.

120 9q34) likely to contain genes that influence substance dependence vulnerability (DV) in adolescence.

121 Major depression among 602 patients with substance dependence was classified as occurring before

122 The risk of substance dependence was elevated among relatives of bul

123 environmental risk factors for psychoactive substance dependence was similar in males and females.

124 Substance dependence was ubiquitous (95.2%), with 61.7%

125 for anxiety disorders, major depression, and substance dependence were approximately three times as h

126 high rates of alcohol, marijuana, and other substance dependence were found.

127 Rates of specific substance dependence were markedly increased in relative

128 ies with the presence or absence of paternal substance dependence were subdivided into those with and

129 d the association between OPRM1 variants and substance dependence, when sex and age of subjects and a

130 with chronic psychotic illness and comorbid substance dependence who entered a specialized day hospi

131 ctional status of families with fathers with substance dependence with or without comorbid antisocial

132 eceptor system is increasingly recognized in substance dependence, with higher mu-opioid receptor (MO

133 filiation with deviant peers than those with substance dependence without antisocial personality diso

134 =34) did not differ markedly from those with substance dependence without antisocial personality diso